AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,934,566 | -12.0% | 805,437 | +0.7% | 0.00% | -20.0% |
| Q2 2023 | $22,645,011 | +2.2% | 799,612 | -17.1% | 0.01% | 0.0% |
| Q1 2023 | $22,146,801 | -49.5% | 964,162 | -38.3% | 0.01% | -50.0% |
| Q4 2022 | $43,889,939 | -13.9% | 1,563,032 | -13.3% | 0.01% | -16.7% |
| Q3 2022 | $50,981,000 | +37.3% | 1,802,705 | +7.6% | 0.01% | +50.0% |
| Q2 2022 | $37,131,000 | -29.8% | 1,674,813 | -7.8% | 0.01% | -27.3% |
| Q1 2022 | $52,899,000 | -14.4% | 1,817,201 | -3.4% | 0.01% | -8.3% |
| Q4 2021 | $61,827,000 | -27.7% | 1,880,931 | +1.6% | 0.01% | -33.3% |
| Q3 2021 | $85,474,000 | -22.7% | 1,852,099 | -7.7% | 0.02% | -28.0% |
| Q2 2021 | $110,536,000 | +54.4% | 2,005,744 | +44.7% | 0.02% | +47.1% |
| Q1 2021 | $71,596,000 | -13.9% | 1,386,424 | -27.7% | 0.02% | -19.0% |
| Q4 2020 | $83,143,000 | +8.3% | 1,918,849 | -12.5% | 0.02% | -4.5% |
| Q3 2020 | $76,737,000 | -28.0% | 2,192,489 | +10.0% | 0.02% | -31.2% |
| Q2 2020 | $106,621,000 | +35.3% | 1,993,663 | -10.2% | 0.03% | +14.3% |
| Q1 2020 | $78,795,000 | -28.5% | 2,220,835 | -3.7% | 0.03% | 0.0% |
| Q4 2019 | $110,146,000 | +165.6% | 2,306,726 | +80.2% | 0.03% | +133.3% |
| Q3 2019 | $41,469,000 | -45.5% | 1,279,906 | -16.1% | 0.01% | -45.5% |
| Q2 2019 | $76,090,000 | -31.0% | 1,525,446 | -6.8% | 0.02% | -33.3% |
| Q1 2019 | $110,337,000 | +81.9% | 1,636,073 | +24.4% | 0.03% | +73.7% |
| Q4 2018 | $60,655,000 | -36.6% | 1,315,447 | +6.0% | 0.02% | -24.0% |
| Q3 2018 | $95,730,000 | -11.6% | 1,241,315 | -3.5% | 0.02% | -16.7% |
| Q2 2018 | $108,296,000 | +15.0% | 1,285,717 | +11.7% | 0.03% | +25.0% |
| Q1 2018 | $94,154,000 | +51.4% | 1,151,304 | +5.9% | 0.02% | +60.0% |
| Q4 2017 | $62,175,000 | -4.3% | 1,087,557 | +11.8% | 0.02% | -6.2% |
| Q3 2017 | $64,958,000 | +85.4% | 973,156 | +42.9% | 0.02% | +77.8% |
| Q2 2017 | $35,042,000 | -7.6% | 681,093 | +4.9% | 0.01% | -10.0% |
| Q1 2017 | $37,909,000 | +1086.9% | 649,124 | +748.0% | 0.01% | +900.0% |
| Q4 2016 | $3,194,000 | +5.0% | 76,545 | +32.9% | 0.00% | 0.0% |
| Q3 2016 | $3,043,000 | +71.6% | 57,607 | +36.1% | 0.00% | 0.0% |
| Q2 2016 | $1,773,000 | +9.5% | 42,316 | +6.1% | 0.00% | 0.0% |
| Q1 2016 | $1,619,000 | -76.2% | 39,893 | -62.0% | 0.00% | -50.0% |
| Q4 2015 | $6,814,000 | +244.0% | 104,963 | +274.0% | 0.00% | +100.0% |
| Q3 2015 | $1,981,000 | -75.7% | 28,063 | -61.8% | 0.00% | -66.7% |
| Q2 2015 | $8,169,000 | +501.1% | 73,498 | +409.9% | 0.00% | – |
| Q1 2015 | $1,359,000 | -79.6% | 14,415 | -75.7% | 0.00% | -100.0% |
| Q4 2014 | $6,657,000 | +431.7% | 59,419 | +191.1% | 0.00% | – |
| Q3 2014 | $1,252,000 | +417.4% | 20,412 | +286.9% | 0.00% | – |
| Q2 2014 | $242,000 | -6.6% | 5,276 | -51.2% | 0.00% | – |
| Q4 2013 | $259,000 | – | 10,812 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |